Disruptive Dozen | World Medical Innovation Forum - Gene and Cell Therapy
Boston
May 2–4, 2022

Disruptive Dozen

12 Most Disruptive Technologies

The “Disruptive Dozen” results from interviews of one hundred Mass General Brigham senior Harvard faculty followed by a rigorous selection process to identify the twelve mostly likely to have significant impact on gene and cell therapy in the next 18 months.

2021 | Digital Health Disruptive Dozen

The culture of innovation at Mass General Brigham fosters a good deal of discussion about emerging technologies and which ones will have the biggest impact. The passion of clinicians and researchers drives a continuous dialogue on what state-of-the-art medical technologies are just over the horizon and their potential to help patients. The Disruptive Dozen is a process that results in a rank ordered list of 12 digital health-enabled technologies that leading Mass General Brigham faculty feel will have the greatest impact on healthcare in the next few years.

2020 | Digital Health Disruptive Dozen

The culture of innovation at Mass General Brigham fosters a good deal of discussion about emerging technologies and which ones will have the biggest impact. The passion of clinicians and researchers drives a continuous dialogue on what state-of-the-art medical technologies are just over the horizon and their potential to help patients. The Disruptive Dozen is a process that results in a rank ordered list of 12 digital health-enabled technologies that leading Mass General Brigham faculty feel will have the greatest impact on healthcare in the next few years.

2019 | Artificial Intelligence Disruptive Dozen

The culture of innovation at Brigham and Women’s Hospital and Massachusetts General Hospital fosters a good deal of discussion about emerging technologies and which ones will have the biggest impact. The passion of clinicians and researchers drives a continuous dialogue on what state-of-the-art medical technologies are just over the horizon and their potential to help patients. The Disruptive Dozen is a process that results in a rank ordered list of 12 AI-enabled technologies that leading Mass General Brigham faculty feel will have the greatest impact on healthcare in the next few years.

2018 | Artificial Intelligence Disruptive Dozen

The culture of innovation throughout Mass General Brigham naturally fosters robust discussions about new “disruptive” technologies and which ones will have the biggest impact on health care. The Disruptive Dozen was created to identify and rank the technologies that Mass General Brigham faculty feel will break through over the next decade to significantly improve health care. This year, the Disruptive Dozen focuses on relevant advances and opportunities in artificial intelligence (AI).

2017 | Cardiovascular Disruptive Dozen

The culture of innovation at Brigham and Women’s Hospital and Massachusetts General Hospital—throughout all of Mass General Brigham and collaborating institutions—naturally fosters a good deal of discussion about new “disruptive” technologies and which ones will have the biggest impact in bringing novel complex health care products and services to greater levels of affordability and accessibility. The mission of Mass General Brigham clinicians and researchers to provide the best care for patients drives a continuous dialogue on what state-of-the-art medical technologies are just over the horizon. The Disruptive Dozen was created to identify and rank the most disruptive technologies that Mass General Brigham leading faculty feel will break through over the next decade in cardiovascular and cardiometabolic care.

2016 | Cancer Disruptive Dozen

Leading Harvard faculty from the Brigham and Women’s Hospital, Massachusetts General Hospital and Dana-Farber nominated the technologies that they believe will have the greatest impact on cancer care during the next decade. A rigorous process was used to choose the 12 technologies that represent their consensus on the one’s that will most influence care in the ten years. The technologies were featured as part of the World Medical Innovation Forum, an annual collaborative innovation event held in Boston to examine the state of health care and innovation in a chosen medical discipline. The 2016 Forum, which took place April 25-27 focused on cancer.

2015 | Neuroscience Disruptive Dozen

The culture of innovation at Brigham and Women’s Hospital, Massachusetts General Hospital, McLean Hospital and Spaulding Rehabilitation Network – throughout all of Mass General Brigham — naturally fosters a good deal of discussion about new “disruptive” technologies and which ones will have the biggest impact. The passion of Mass General Brigham clinicians and researchers to provide the best care for patients drives a continuous dialogue on what state-of-the-art medical technologies are just over the horizon. The Disruptive Dozen was created to identify and rank the most disruptive technologies that Mass General Brigham leading faculty feel will breakthrough over the next decade in neurological care.

The Process

The Selection

Each year, a group of leading Mass General Brigham faculty gather to form a committee of “selectors” to jointly choose and rank the final 12 technologies. The selection committee moderators are supported by Mass General Brigham Innovation staff. To receive consideration for the final Disruptive Dozen, nominated technologies have to meet the following criteria

Criteria 1
The innovation has to have the strong potential for significant clinical impact at some point in the next 18 months and offer significant patient benefit in comparison to current practices. The innovation may also have a significant benefit to the delivery/efficiency of the selected field.

Criteria 2
Nominated field-related innovations have to have a high probability of successful commercial deployment—e.g., payers will be expected to support it.

Criteria 3
The innovation must be on the market sometime within the next 18 months.

The Ranking

Round 1

The initial pass of the nominations by the selection committee eliminates all technologies that don’t meet the criteria or don’t have a realistic potential of being ranked in the top 15. The moderators name each technology and ask panel members to vote “yes” or “no” to move the technology to the next round. One “yes” vote is enough to advance the technology.

Round 2
The moderators describe the candidate technology, pointing out salient points, and then ask for comments from committee members. After a discussion of the pros and cons of the technology, panel members vote A, B, or C with a raise of the hand. Innovation staff record the voting.

A. It’s highly probable that the technology will significantly influence the selected field within the next 18 months.
B. It’s probable that the technology will significantly influence the selected field within the next 18 months.
C. It’s not likely that the technology will significantly influence the selected field within the next 18 months.

Round 3
Each surviving technology earns a score with overall rank tied to the size of the score—i.e., the higher the score, the better. Innovation staff report this initial ranking of all technologies.

Final Scores and Announcement

Selection committee members jointly rank the innovations from 1 to 12 using the initial scoring and further discussion. The selection committee ranking is final and is announced in a one-hour panel on the last day of the World Medical Innovation Forum. The session is moderated by the Forum Co-Chairs and features 12 faculty members selected to briefly comment on each technology.

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA